| Patient |
sex |
Age |
Initial VA(Before treatment) |
Final VA |
eye |
Follow-up(mo) |
Injection |
MT Pretreatment |
MT Posttreatment |
Investigation(s) |
Serology status |
| 1 |
F |
27 |
0.08 |
20/30 |
OD |
24 m |
Avastin |
395 |
300 |
FA, OCT |
IgG, positive; IgM, negative |
| 2 |
F |
32 |
0.07 |
20/200 |
OS |
6 m |
Avastin |
410 |
250 |
FA, OCT |
IgG, positive; IgM, negative |
| 3 |
M |
24 |
0.06 |
20/200 |
OD |
12 m |
Avastin |
380 |
215 |
FA, OCT |
IgG, positive; IgM, negative |
| 4 |
M |
16 |
0.05 |
20/100 |
OS |
15 m |
Avastin |
400 |
250 |
FA, OCT |
IgG, positive; IgM, negative |
| 5 |
F |
37 |
0.07 |
20/100 |
OS |
15 m |
ranibizumab |
410 |
235 |
FA,OCT |
IgG, positive; IgM, negative |
|
